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Abstract (200 words max): 
 
BRCA1 BRCA2 mutational spectrum in the Middle East, North Africa, and 
Southern Europe is not well characterized. The unique history and cultural practices 
characterizing these regions, often involving consanguinity and inbreeding, plausibly 
led to the accumulation of population-specific founder PSVs. To determine recurring 
BRCA PSVs in these locales, a search in PUBMED, EMBASE, BIC, and CIMBA) was 
carried out combined with outreach to researchers from the relevant countries for 
unpublished data. We identified 232 PSVs in BRCA1 and 239 in BRCA2 in 25 of 33 
countries surveyed. Common PSVs that were detected in 4 or more countries were, 
c.5266dup (p.Gln1756Profs), c.181T>G (p.Cys61Gly), c.68_69del (p.Glu23Valfs), 
c.5030_5033del (p.Thr1677Ilefs), c.4327C>T (p.Arg1443Ter), c.5251C>T 
(p.Arg1751Ter), c.1016dup (p.Val340Glyfs), c.3700_3704del (p.Val1234Glnfs), 
c.4065_4068del (p.Asn1355Lysfs), c.1504_1508del (p.Leu502Alafs), c.843_846del 
(p.Ser282Tyrfs), c.798_799del (p.Ser267Lysfs) and c.3607C>T (p.Arg1203Ter) in 
BRCA1 and c.2808_2811del (p.Ala938Profs), c.5722_5723del (p.Leu1908Argfs), 
c.9097dup (p.Thr3033Asnfs), c.1310_1313del (p. p.Lys437Ilefs) and c.5946del 
(p.Ser1982Argfs) for BRCA2. Notably, some mutations [e.g., p.Asn257Lysfs 
(c.771_775del)] were observed in unrelated populations. Thus, seemingly genotyping 
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Introduction (300 words max): 
 
Breast cancer (BC) is the most common female malignancy worldwide with a 
global age standardized rate (ASR) of 43.1/100,000 women (Cancer Incidence in five 
contents, n.d.). BC rates in developed countries are significantly higher than those in 
developing countries (Cancer Incidence in five continents, n.d.). Ethnicity impacts BC 
risk: in Israel, BC ASR in Jewish women is 89.4/100,000 and in non-Jews - 
56.1/100000 (Cancer Incidence Table, n.d.). Moreover, the median age at diagnosis in 
Mediterranean countries is younger compared with Western European countries and is 
often diagnosed in premenopausal women (Al-Kuraya et al., 2005; Atoum & Al- 
Hourani, n.d.; Bener, Ayub, Kakil, & Ibrahim, n.d.; El Saghir et al., 2007). These 
 
 
differences in BC phenotype between populations may be attributed to differences in 
BC risk factors, including genetic predisposition. 
Germline pathogenic sequence variants (PSVs) in BRCA1 and BRCA2 are the 
predominant contributors to inherited BC. Since the mid 1990’s, more than 3500 
germline PSVs have been reported in both genes (“CIMBA - Consortium of 
Investigators of Modifiers of BRCA1/2 —,” n.d.; “Online Research Resources 
Developed at NHGRI,” n.d.). BRCA pathogenic PSVs in most world outbred 
populations – are unique (i.e., family specific) (Rebbeck et al., 2016). In some 
populations, the spectrum of BRCA PSVs is much more limited, with a few “founder 
PSVs". A relevant Mid-Eastern example are Ashkenazi Jews: three predominant PSVs 
(185delAG, 5382InsC*BRCA1 and 6174delT*BRCA2, e.g, c.66_67del, c.5266dup in 
BRCA1 and c.5946del in BRCA2) account for most of germline PSVs in high-risk 
women of Ashkenazi origin (Abeliovich et al., 1997). Given the traditions and cultural 
breeding habits in the Middle East, North Africa, and some South European countries, 
it seems plausible that in some populations of the region, founder and/or recurring 
BRCA PSVs may be detected. Indeed, some populations in these regions (e,g, Greek, 
North Africans, Jewish Ashkenazim) present recurring mutations (Bu et al., 2016; 






Data type Tables 
Data acquisition method Survey, NGS, Sanger sequencing. 
Data format Filtered and analyzed 
Experimental factors Irrelevant 
Experimental features Data collecftion from published manuscripts in the public doam,in 
and outreach and unpublished data from the PI’s of leading 
laboratories in the relevant geographical regions 
Data source location Published manucsrpits and unpublished data 
Data accessibility Data were deopisted in the LOVD data base under Laitman 2019, 





https://databases.lovd.nl/shared/individuals reference query- 
Laitman 2019, submitted 
 
Impact of Data (200 words max): 
 
The data presented herein provide the framework for a possible first pass genotyping platform in 
populations residing in the Middle East, North Africa, and South Europe. This platform should 
include the pathogenic sequence variants (PSVs) that were reported in more than 4 countries. As 
such, this genotyping platform may facilitate rapid, cheap, targeted BRCA genotyping for 
 
 
unselected breast, ovarian cancer cases, asymptomatic individuals from high-risk families, and 
possibly enable population based screening. 
 
 
Experimental Design, Materials and Methods: 
 
Editorial Policies and Ethical Considerations-The data presented herein were obtained 
by protocols approved by the ethics committees of the contribution centers in their 
respective countries. 
A search for “BRCA1” and “BRCA2” and “Middle East”, “North Africa”, 
“South East Europe”, “Arab”, “Muslim”, “Jewish”, specific country names (Morocco, 
Tunisia, Algeria, Libya, Egypt, Saudi Arabia, Jordan, Israel, Cyprus, Italy (the regions 
located in the South), Syria, Lebanon, Turkey, Greece, Malta, Macedonia, Albania, 
Serbia, Slovenia, Bulgaria, Yugoslavia, Montenegro, Bosnia, Romania, Armenia, 
Georgia, Iran, Iraq, Qatar, United Arab Emirates, Oman, Bahrain, and Yemen) was 
carried out using PUBMED, Google Scholar, and EMBASE. In addition, search by the 
specific country names in BIC database (Breast Cancer Information Core, n.d.) was 
also carried out. 
All corresponding authors from the list of publications using the above listed 
scheme were contacted by mail and offered participation and contributing their 
unpublished data to the current study. 
The CIMBA dataset (http://cimba.ccge.medschl.cam.ac.uk) was also searched 
for pathogenic PSVs deposited from the following countries represented in CIMBA 
(Greece, Cyprus, Israel, and Iran). 
 
 
Sequencing data were derived from individuals that were genotyped for BRCA 
germline PSVs in the context of a variety of studies: population-based cohorts, 
consecutive breast and/or ovarian cancer, early onset BC (i.e., BC diagnosed under age 
40 years) or based on high-risk criteria (National Comprehensive Cancer Network, 
2018). No attempt was made in the context of this study to distinguish between the 
different types of ascertainment and eligibility in the original studies. Only studies that 
performed complete sequencing of the BRCA1 and BRCA2 genes were included. 
Reporting was limited to point PSVs and small indels and to bona fide PSVs. Large 
genomic rearrangements and unclassified or non-pathogenic missense PSVs or 





Table 1 displays the most common and recurring BRCA1 and BRCA2 pathogenic and likely 
PSVs that were reported in 4 or more countries. The PSVs that are enumerated in table 2 are 
those reported in more than one country. Table 3 summarizes all other PSVs, even those reported 





In the present study, an attempt to comprehensively collect and tabulate all 
documented PSVs in both the BRCA1 and BRCA2 genes in a defined geographical 
region was carried out. Of the total of 232 BRCA1 and 239 BRCA2 PSVs in the 
targeted populations, there are 38 (BRCA1) and 42 (BRCA2) PSVs that are recurring 
within the same population, or closely related populations (table 2). In these 
 
 
populations, the next logical step should be genotyping of unselected BC and ovarian 
cancer cases, and, wherever feasible, the general population, to determine the rates of 
the top occurring founder PSVs in these cohorts. Given the increased capacity of 
genotyping platforms, at a minimum the top recurring 18 BRCA PSVs should be 
considered in all relevant populations. Indeed, in Israel “first pass BRCA genotyping” 
of a cluster of recurring PSVs (ranging from a minimum of the 3 recurring Ashkenazi 
PSVs to a maximum of 14 PSVs that have been described in more than 2 Israeli 
families of diverse ethnicity, depending on the policy of each medical center) is 
currently being offered to all BC and ovarian cancer cases, without preselection. The 
reasons for this inclusive approach are multiple: the ease and cost of genotyping, the 
fast turnaround time, and the rates of these recurring PSVs in unselected BC (up to 
12% in Ashkenazi Jews) and ovarian cancer cases (~30% of all ovarian cancer cases 
with higher rates in Ashkenazim) (Abeliovich et al., 1997; Modan et al., 2009; 
Rubinstein, 2004), combined with the penetrance rates that are similar in high risk 
families and the PSV carriers identified through population screens (Manchanda et al., 
2015). Moreover, these high rates in cancer cases and the rates in the general 
population, ~2.5% in Ashkenazim (Roa, Boyd, Volcik, & Richards, 1996), have led to 
a scientifically valid initiative to offer this limited genotyping platform to all 
Ashkenazi and Iraqi Jews, regardless of health status (Levy-Lahad, Lahad, & King, 
2015, p.). Cost effectiveness analysis has shown that at least in the Ashkenazi 
population this approach is indeed cost effective (Manchanda et al., 2014). Moreover, 
a similar "first-pass" BRCA genotyping scheme is also applied in a cost-effective 
manner for the Greek population, as six recurrent BRCA1 mutations account for 
 
 
approximately 60% of the total mutation spectrum for both BRCA genes 
(Konstantopoulou et al., 2014). These include three PSVs in exon 20 [(c.5212G>A - 
p.Gly1738Arg); (c.5251C>T - p.Arg1751Ter); (c.5266dup - p.Gln1756Profs)] and 
three large genomic deletions (deletion of exon 20, exon 24, and exons 23 and 24). All 
three large deletions as well as the c.5212G>A - p.Gly1738Arg PSV have been 
characterized as population-specific founder mutations by haplotype analysis 
(Anagnostopoulos et al., 2008; Apostolou et al., 2017; Pertesi, Konstantopoulou, & 
Yannoukakos, 2011). 
Applying this scheme to other countries in the region covered in the current 
study, may prove cost effective as well, and help in identifying high-risk, 
asymptomatic individuals who do not fulfil the currently practiced criteria for BRCA 
genotyping eligibility. 
Recurring, identical PSVs in the BRCA1 and BRCA2 genes are either “founder 
PSVs” or represent a PSV hot-spot, reviewed by Ferla (Ferla et al., 2007). One indirect 
(and admittedly imprecise) way of distinguishing between these two possibilities, is 
assessing the rates of these PSVs in geographically and historically unrelated, distinct 
populations. Indeed, the 999del5 (c.771_775del) BRCA2 PSV, clearly an Icelandic 
founder PSV (Thorlacius et al., 1997) was reported in Egyptian and Jordanian 
individuals. Similarly, the 1100delAT (herein referred to as c.981_982del) BRCA1 
PSV that was described in Jewish Libyan families (Gal et al., 2002) was also reported 
to recur in Chinese non-Jewish families (Li et al., 2008). Interestingly, the p.Cys61Gly 
and 5266dup BRCA1 PSVs, seem to be the most prevalent PSVs in the present study, 
and were reported in 11 and 16 countries, respectively. These are the most common 
 
 
PSVs in Poland (Górski et al., 2000) and other geographically related countries like 
Belarus (Uglanitsa et al., 2010). The prevalence and distribution of these PSVs in 
countries from the Middle East and North Africa, a region for which there is no 
recorded massive population exchange or North European influx is puzzling. Indeed, 
haplotype analysis of the 5266dup has shown that this PSV arose ~1800 years ago in 
Northern Europe (Hamel et al., 2011). The possibility of a common ancestor is still 
valid and can only be resolved using a haplotype analysis of these PSV carriers in a 
trio setting. Previous analysis of Jewish and non-Jewish individuals who carry the 
p.Cys61Gly PSV was suggestive of a common origin (Kaufman, Laitman, Gronwald, 
Lubinski, & Friedman, 2009). Several explanations should be considered in accounting 
for a seemingly common origin for a single PSV in distinct populations: a few 
individuals who migrated from one geographical region to another with no historical 
documentation of this migration, as the number of migrants was limited; an ancient, 
historically unrecognized common ancestor. In addition, the possibility of having a 
rare hot spot or a chance occurrence may also underlie identical PSVs in distinct 
populations, albeit having a different haplotype. From the historical perspective, the 
Middle East, South Europe and North Africa are regions where human culture has 
thrived and were prone to multiple conquests by regional forces (the ancient Iranians, 
Romans, Greek, Arabs, the crusaders, are notable examples), conquests that have re- 
shaped and re-defined the borders of current countries. In addition, some conquerors 
applied an exile strategy as a means of asserting their rule over these territories. It is 
plausible that during such massive exiles (e.g., Jews from current day Israel to 
 
 
Babylon, mass enslavement by the Roman Empire) a few PSV carriers may have been 
embedded in these new locales. 
Much of the genetic trace of the more remote and recent demographic and 
migratory events has been fruitfully elucidated by examining the phylogenies of the 
uniparentally inherited mitochondrial DNA (Behar et al., 2006, 2008) and Y 
chromosome (Behar et al., 2017; Hammer et al., 2000; Karmin et al., 2015), and by 
investigating autosomal biparental variation (Behar et al., 2010; Haber et al., 2013). 
Overall, the emerging pattern is of a multilayered demographic history characterizing 
contemporary Middle Eastern populations. First, it is apparent that Middle Eastern 
populations share a distinctive background genetic layer that is readily separable from 
components dominating other continents (Behar et al., 2010; Haber et al., 2013). 
Accordingly, within a global context, Middle Eastern populations are found in close 
genetic proximity to each other pointing to a common ancient ancestral deme. 
However, within the Middle Eastern variation, various populations cluster separately 
from each other, suggesting more recent isolation and inbreeding. As the level of the 
uniploids, evidences from the Y-chromosome and mtDNA suggest local founding 
events (Badro et al., 2013), specific to a given population, and sometimes down to the 
village level (Shlush et al., 2008). For example, the Ashkenazi Jewish population was 
repeatedly demonstrated to derive its ancestral origins from the Levant and Europe 
(Atzmon et al., 2010; Behar et al., 2010), and strong isolation from its hosting 
population were suggestive for a strong parental founding event (Behar et al., 2006, 
2017). This was suggested to be the reason for the high incidence of rare autosomal 
recessive disorders characterizing the population. Hence, it seems plausible to suggest 
 
 
that the same mechanisms leading to the founding events proven for the mtDNA 
(Behar et al., 2006), Y-chromosome (Behar et al., 2004), and rare recessive disorders 
among Ashkenazi Jews (Baskovich et al., 2016), played also a major role in the 
accumulations of the three BRCA1/2 PSVs in this population. Using haplotype analysis 
of individuals from diverse and unlikely related ethnicities may allow for 
distinguishing some of these possibilities. Indeed, haplotype analysis of the c.66_67del 
BRCA1 PSV has shown that among Ashkenazi Jews, non-Ashkenazi Jews, and non- 
Jewish Hispanics the PSV has a common haplotype whereas the haplotype in 
Malaysians and English non-Jews is distinct (Laitman et al., 2013). 
In conclusion, in a geographically defined region, a few BRCA1 and BRCA2 
PSV have been reported with a handful of these PSV recurring within these 
populations or shared by some distinct ethnicities. Regardless of the mechanism that 
has led to such restricted PSVs reality, these PSVs may be considered as "first pass" 
BRCA genotyping for defined subsets of individuals (e.g., high risk families, 
consecutive breast/ovarian cancer cases, population screens) in these geographical 
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BRCA1 5382insC c.5266dup p.Gln1756Profs rs80357906 Bulgaria, Croatia, Egypt, 
Greece, Iran, Israel, Italy, 
Lebanon, Macedonia, 
Romania, Serbia, Slovenia, 
















BRCA1 C61G c.181T>G p.Cys61Gly rs28897672 Algier, Bulgaria, Croatia, 












BRCA1 185delAG c.68_69del p.Glu23Valfs rs80357713 Egypt, Greece, Iran, Israel, 








BRCA1 5149del4 c.5030_5033del p.Thr1677Ilefs rs80357862 Bulgaria, Greece, Italy, 





BRCA1 R1443X c.4327C>T p.Arg1443Ter rs41293455 Egypt, Greece, Italy, Kuwait, 
































BRCA1 917delTT c.798_799del p.Ser267Lysfs rs80357724 Algier, Italy, Morocco, 
Tunisia 
26 23697973 
BRCA1 3726C>T c.3607C>T p.Arg1203Ter rs62625308 Greece, Israel, Italy, Turkey 36 12655560 
 
 
BRCA2 3036del4 c.2808_2811del p.Ala938Profs rs80359352 Cyprus, Iran, Israel, Italy, 






BRCA2 5950delCT c.5722_5723del p.Leu1908Argfs rs80359531 Algier, Bulgaria, Greece, Iran, 





BRCA2 9326insA c.9097dup p.Thr3033Asnfs rs397507419 Bulgaria, Greece, Romania, 
Turkey 
27  







BRCA2 6174delT c.5946del p.Ser1982Argfs rs80359550 Bulgaria, Greece, Iran, Israel 1093 26183948 
 
 
Table 2: mutations in BRCA1 and BRC2 recurring in more than one country 
Gene BIC designation HGVS designation HGVS:protein 
level 









BRCA1 P1812A c.5434C>G p.Pro1812Ala rs1800751 Greece, Israel 2 PC 
BRCA1 3480delAG c.3599_3600del p.Gln1200Argfs rs398122674 Albania, Greece - PC 
BRCA1 R1699W c.5095C>T p.Arg1699Trp rs55770810 Morroco, Saudi 
Arabia 
18 23697973 
BRCA1 W1508X c.4524G>A p.Trp1508Ter rs80356885 Israel, Saudi 
Arabia 
23 27082205 
BRCA1 W1815X c.5444G>A p.Trp1815Ter rs80356962 Lebanon, Turkey 4 10952777 
BRCA1 Y978X c.2934T>G p.Tyr978Ter rs80357115 Iran, Israel 26 11248423 
BRCA1 Q1182X c.3544C>T p.Gln1182Ter rs80357296 Turkey, Bulgaria 1 PC 
BRCA1 2388delG c.2269del p.Val757Phefs rs80357583 Israel, Slovenia 10 21232165 
BRCA1 5454delC c.5335del p.Gln1779Asnfs rs80357590 Croatia, Egypt 5 20579331 
BRCA1 2138delA c.2019del p.Glu673Aspfs rs80357626 Serbia, Turkey 7 23635950 
BRCA1 343del4 c.224_227del p.Glu75Valfs rs80357697 Greece, Israel 2 PC 
BRCA1 5055delG c.4936del p.Val1646Serfs rs80357705 Israel, Turkey 4 10952777 
BRCA1 4160delAG c.4041_4042del p.Gly1348Asnfs rs80357727 Israel, Tunisia 7 23697973 
BRCA1 969ins7 c.844_850dup p.Gln284Leufs rs80357989 Serbia, Slovenia 2 12461697; 
23635950 
BRCA1 IVS21+1G>A c.5332+1G>A  rs80358041 Algier, Israel 2 26997744 
BRCA1 IVS11+1G>A c.4096+1G>A  rs80358178 Cyprus, Greece, 
Turkey 
5 21156238 




BRCA1 C44F c.131G>T p.Cys44Phe rs80357446 Lebanon, Kuwait 12 23289006; 
PC 
BRCA1 R1835X c.5503C>T p.Arg1835Ter rs41293465 Greece, Italy, 
Turkey 
74 10952777 




BRCA1 C64R c.190T>C p.Cys64Arg rs80357064 Greece, Italy 12 PC 




BRCA1 3875del4 c.3756_3759del p.Ser1253Argfs rs80357868 Greece, Italy 130 17453335 
 
 
BRCA1 5083del19 c.4964_4982del p.Ser1655Tyrfs rs80359876 Greece, Italy 48 PC 
BRCA1 Q1537X c.4609C>T p.Gln1537Ter rs80357229 Iran, Saudi Arabia 1 30199306 
BRCA1 A1708E c.5123C>A p.Ala1708Glu rs28897696 Israel, Italy 46 21063910 
BRCA1 3228_3229delAG c.3228_3229del p.Gly1077Alafs rs80357635 Israel, Italy 28 PC 
BRCA1 1100delAT c.981_982del p.Cys328Terfs rs80357772 Israel, Italy 13 PC 
BRCA1 2530delAG c.2411_2412del p.Gln804Leu rs80357664 Italy, Lebanon 15 257773438; 
PC 
BRCA1 E368X c.1102G>T p.Glu368Ter rs80357139 Italy, Macedonia 1 24052750; 
29335924 
BRCA1 2767ins4 c.2649_2650insGGCA p.Thr884Glyfs rs886038003 Greece, Iran - PC; 
11248423 





















BRCA1 1640_1650del10 c.1521_1531del p.Thr509Serfs - Albania, Greece - PC 
BRCA2 9158delA c.8930del p.Tyr2977Phefs rs869320799 Greece, Italy - PC 
BRCA2 9254del5 c.9026_9030del p.Tyr3009Serfs rs80359741 Israel, Turkey 16 PC; 
29774317 




BRCA2 5164del4 c.4936_4939del p.Glu1646Glnfs rs80359473 Israel, Slovenia 28 12461697 
BRCA2 4075delGT c.3847_3848del p.Val1283Lysfs rs80359405 Greece, Israel 64 PC 
BRCA2 I2627F c.7879A>T p.Ile2627Phe rs80359014 Greece, 
Macedonia 
7 29335924 
BRCA2 S1882X c.5645C>A p.Ser1882Ter rs80358785 Greece, Iran, Italy 27 PC; 
26109977 
BRCA2 E510X c.1528G>T p.Glu510Ter rs80358438 Algier, Slovenia 1 12461697; 
26997744 
BRCA2 9910delA c.9682del p.Ser3228Valfs rs398122618 Greece, Bulgaria - 26183948 




BRCA2 6719delAGTT c.6491_6494del p.Gln2164Argfs rs397507862 Croatia, Slovenia - 21232165 
BRCA2 3979insA c.3751dup p.Thr1251Asnfs rs397507683 Iran, Israel - PC; 
26109977 
BRCA2 Q2893X c.8677C>T p.Gln2893Ter rs397507409 Iran, Israel - PC; 
26109977 
BRCA2 4642del4 c.4415_4418del p.Lys1472Thrfs rs397507333 Iran, Greece - 12100744 
BRCA2 4391delCTinsA c.4163_4164delinsA p.Thr1388Asnfs rs276174843 Serbia, Turkey - 21954532 
BRCA2 7463InsG c.7235_7236insG p.Lys2413Ter rs397507906 Algier, Morocco 1 23697973; 
20683152 





BRCA2 999del5 c.771_775del p.Asn257Lysfs rs80359675 Egypt, Jordan 14 29409476; 
20579331 
BRCA2 Q1408X c.4222C>T p.Gln1408Ter rs80358663 Albania, Italy 4 PC 
BRCA2 K2013X c.6037A>T p.Lys2013Ter rs80358840 Greece, Italy 16 PC 
 
 
BRCA2 4512insT c.4284dup p.Gln1429Serfs rs80359440 Greece, Italy 4 2085629; 
PC 
BRCA2 6024delTA c.5796_5797del p.His1932Glnfs rs80359537 Greece, Italy 9 11754111; 
PC 
BRCA2 9474insA c.9253dup p.Thr3085Asnfs rs80359752 Greece, Italy 19 PC 
BRCA2 8765delAG c.8537_8538del p.Glu2846Gly rs80359716 Israel, Italy 76 PC 
BRCA2 IVS2+1G>A c.67+1G>A  rs81002796 Israel, Italy 4 PC 
BRCA2 5301insA c.5073dup p.Trp1692Metfs rs80359480 Italy, Morocco 29 23697973 
BRCA2 4366insTT c.4139_4140dup p.Lys1381Leufs rs276174842 Croatia, Serbia 1 23635950 





BRCA2 R2336P c.7007G>C p.Arg2336Pro rs28897743 Greece, Israel, 
Saudi Arabia 
26 29297111 
BRCA2 2041insA c.1813dup p.Ile605Asnfs rs80359308 Albania, Greece, 
Slovenia 
75 12461697 





















BRCA2 6503delTT c.6275_6276del p.Leu2092Profs rs11571658 Greece, Italy 95 PC 
BRCA2 6714del4 c.6486_6489del p.Lys2162Asnfs rs80359598 Italy, Slovenia 1 PC; 
27882536 
BRCA2 IVS16-2A>G c.7806-2A>G  rs81002836 Italy, Slovenia 5 PC; 
12461697 
BRCA2 IVS24-1G>C c.9257-1G>C  rs81002889 Israel, Jordan 2 20960228; 
29335924 
BRCA2 6630del5 c.6405_6409del p.Asn2135Lysfs rs80359584 Italy, Turkey 30 10952777; 
PC 
BRCA2 8138del5 c.7913_7917del p.Phe2638Ter rs80359686 Bulgaria, Greece 24 26183948; 
PC 
























































BRCA1 Algier  138del29 c.19_47del p.Arg7Cysfs rs80359871 1 23697973 
BRCA1 Algier  202delTG c.83_84del p.Leu28Argfs rs80357728 1 20683152 
BRCA1 Algier  2049delC c.1817del p.Pro606Leufs rs397508910 - 23289006 
BRCA1 Algier  3574delT c.3715del p.Ser1239Leufs rs397509096 - 23289006 
BRCA1 Algier  3834delTCTinsC c.3715_3717delinsC p.Ser1239Profs rs273900714 1 18645608 
BRCA1 Algier  2862delTC c.2602_2603del p.Ser868Terfs rs80357540 1 23289006 
BRCA1 Algier  IVS5+1G>A c.212+1G>A  rs80358042 6 23697973 
BRCA1 Bulgaria  583delA c.465del p.Gln155Hisfs rs483353104 1 26183948 
BRCA1 Bulgaria 1 E1535X c.4603G>T p.Glu1535Ter rs80357366 4 26183948 
BRCA1 Bulgaria 1 5515del7 c.5397_5403del p.Leu1800Glnfs - - 26183948 
BRCA1 Croatia  E1107X c.3319G>T p.Glu1107Ter rs80357106 3 PC 
BRCA1 Croatia  E418X c.1252G>T p.Glu418Ter rs80357083 3 22366370 
BRCA1 Cyprus 2 1819insA c.1700dup p.Asn567Lysfs rs80357784 1 27882536 
BRCA1 Cyprus 2 K614X c.1840A>T p.Lys614Ter rs80357282 1 27882536 
BRCA1 Cyprus 7 5429delG c.5315del p.Phe1772Serfs rs397509261 - 15172753 



















BRCA1 Greece 1 2004A>T c.1885A>T p.Arg629Ter -  PC 
BRCA1 Greece 1 2695delA c.2576del p.Asn859Ilefs -  PC 
BRCA1 Greece 1 1531insCAGT c.1299_1302dup p.Asp435Glnfs -  PC 
BRCA1 Greece 1 3555del4 c.3436_3439del p.Cys1146Leufs rs397509067 - 29310832 
BRCA1 Greece 1 3099delT c.2980del p.Cys994Valfs rs80357502 1 10980541 
BRCA1 Greece 1 Q1409X c.4225C>T p.Gln1409Ter rs886040218 - PC 



















BRCA1 Greece 2 449delG c.331del p.Glu111Lysfs rs886040114 - 24010542 
BRCA1 Greece 1 E1526X c.4576G>T p.Glu1526Ter rs878853294 - PC 
BRCA1 Greece 1 1329insCT c.1210_1211insCT p.Glu404Alafs rs886039934 - 24010542 
BRCA1 Greece 1 4324delA c.4205del p.His1402Leufs rs886040214 - PC 
BRCA1 Greece 2 2623insA c.2504dup p.His835Glnfs rs483353078 - PC 
BRCA1 Greece 1 3744insA c.3624dup p.Leu1209Ilefs rs80357512 2 10980541 
BRCA1 Greece 1 3896delT c.3779del p.Leu1260Tyrfs rs397509107 3 17453335 
BRCA1 Greece 1 L502X c.1505T>G p.Leu502Ter rs886039957 - 24010542 
BRCA1 Greece 3 3741delA c.3624del p.Lys1208Asnfs rs886038020 - 24010542 
BRCA1 Greece 1 269delA c.150del p.Lys50Asnfs rs273897662 1 PC 
 
 
BRCA1 Greece 1 M1V c.1A>G p.Met1Val rs80357287 8 10980541 
BRCA1 Greece 1 3436delC c.3317del p.Pro1106Leufs -  PC 
BRCA1 Greece 4 3494delTC c.3375_3376del p.Pro1126Ilefs rs80357828 1 24010542 



















BRCA1 Greece 1 4286delTG c.4167_4168del p.Ser1389Argfs rs397509144 - 24010542 
BRCA1 Greece 1 3082C>A c.2963C>A p.Ser988Ter rs397507206 - 24010542 
BRCA1 Greece 1 5447delC c.5328del p.Thr1777Glnfs - 2 24010542 
BRCA1 Greece 1 1789del4 c.1670_1673del p.Thr557Lysfs -  PC 
BRCA1 Greece 4 W353X c.1059G>A p.Trp353Ter rs80356935 4 29310832 
BRCA1 Greece 1 5533dupT c.5533dup p.Tyr1845Leufs rs397509294 - PC 
BRCA1 Greece 1 5789del13 c.5557_5569del p.Tyr1853Argfs - 1 PC 
BRCA1 Greece 1 5675del5 c.5556_5560del p.Tyr1853Aspfs rs886040305 - PC 
BRCA1 Greece 1 3277insG c.3158_3159insG p.Val1054Serfs rs80357769 1 10980541 
BRCA1 Greece 1 IVS17-1G>A c.5075-1G>A  rs1800747 1 24667779 
BRCA1 Greece 1 IVS6-2A>G c.302-2A>G  rs80358011 1 20406929 
BRCA1 Greece 2 IVS22+5G>C c.5406+5G>C  rs80358073 2 9354803 
BRCA1 Greece 1 IVS20-1G>A c.5278-1G>A  rs80358099 3 PC 
BRCA1 Greece 1 IVS6-1G>C c.302-1G>C  rs8035811 - PC 
BRCA1 Iran 1 3452delA c.3333del p.Glu1112Asnfs rs80357966 1 PC 
BRCA1 Iran  181insT c.62dup p.Glu23Argfs rs397509303 - PC 
BRCA1 Iran  G1738E c.5213G>A p.Gly1738Glu rs80357450 6 PC 
BRCA1 Iran 1 1803insA c.1684dup p.Ile562Asnfs -  27165220 
BRCA1 Iran  L1418X c.4253T>G p.Leu1418Ter rs397509157 - PC 
BRCA1 Iran 2 IVS2-1G>C c.81-1G>C p.Leu30Ter -  PC 
BRCA1 Iran  L3X c.8T>G p.Leu3Ter -  PC 
BRCA1 Iran 1 1411delT c.1292del p.Leu431Tyrfs rs398122629 - PC 
BRCA1 Iran 2 1687delT c.1568del p.Leu523Trpfs -  27165220 
BRCA1 Iran 1 2374delTAAGT c.2255_2259del p.Leu752Trpfs -  PC 
BRCA1 Iran  1135delA c.1016del p.Lys339Argfs rs80357618 2 25352972 




































BRCA1 Iran 1 Y856X c.2568T>G p.Tyr856Ter rs80356832 3 PC 
BRCA1 Iran 1 3477delGT c.3358_3359del p.Val1120Ter rs80357945 4 PC 












































BRCA1 Israel  Q1273X c.3817C>T p.Gln1273Ter rs80357208 8 PC 

















BRCA1 Israel  1039-1040delCT c.1039_1040del p.Leu347Valfs rs397508827 - PC 
BRCA1 Israel  2543del7 c.2311_2317del p.Pro773Leufs rs1060502354 - PC 
BRCA1 Israel  S864X c.2591C>A p.Ser864Ter rs80357003 1 PC 
BRCA1 Israel  Y1127X c.3381T>G p.Tyr1127Ter rs781319410 - PC 
BRCA1 Israel   c.4359del p.Val1454Tyrfs -  PC 
BRCA1 Italy 1  c.1297del p.Ala433Profs rs80357794 - PC 



















BRCA1 Italy 1  c.882del p.Asp295Thrfs - - PC 



















BRCA1 Italy 1  c.5476C>T p.Gln1826Ter - - 29335924 



















BRCA1 Italy 1  c.3514G>T p.Glu1172Ter rs397509079 - PC 
BRCA1 Italy 1  c.363_364del p.Glu121Aspfs rs886040155 - PC 
BRCA1 Italy 1 3888delGA c.3770_3771del p.Glu1257Glyfs rs80357579 1 PC 
BRCA1 Italy 2 E1302X c.3904G>T p.Glu1302Ter rs80357461 3 PC 
BRCA1 Italy 2 2508delGA c.2389_2390del p.Glu797Thrfs rs80357695 4 PC 



















BRCA1 Italy 1  c.4042G>T p.Gly1348Ter rs886040191 - PC 
BRCA1 Italy 1 IVS20-2delA c.5278-2delA p.Ile1760Serfs - - PC 



















BRCA1 Italy 2 5154del5 c.5035_5039del p.Leu1679Tyrfs rs80357623 7 PC 
BRCA1 Italy 1 L999X c.2995_2996delinsTA p.Leu999Ter rs273899692 1 PC 
BRCA1 Italy 1  c.1375A>T p.Lys459Ter rs886039947 - PC 
BRCA1 Italy 1  c.1513A>T p.Lys505Ter rs397508877 - PC 



















BRCA1 Italy 2  c.1887_1900dup p.Pro634Glnfs rs886039977 - PC 
BRCA1 Italy 1 4408insC c.4289dup p.Ser1431Phefs rs80357556 1 PC 
BRCA1 Italy 1  c.4456del p.Ser1486Valfs rs397509179 - PC 



















BRCA1 Italy 1  c.2350_2351del p.Ser784Valfs - - PC 
 
 
BRCA1 Italy 1  c.3928dup p.Thr1310Asnfs rs886040176 - PC 
BRCA1 Italy 1  c.4453_4454delinsG p.Thr1485Alafs - - PC 
BRCA1 Italy 1  c.815_824dup p.Thr276Alafs rs387906563 - 29335924 
BRCA1 Italy 1 IVS7+2T>G c.441+2T>G  rs397509173 - PC 
BRCA1 Italy 1 IVS3+2T>C c.134+2T>C  rs80358131 2 PC 
BRCA1 Italy 2 IVS18-1G>A c.5153-1G>A  rs80358137 5 PC 
BRCA1 Jordan 1 E1373X c.4117G>T p.Glu1373Ter rs80357259 9 29335924 

















BRCA1 Lebanon  Q804X c.2410C>T p.Gln804Ter rs80356982 2 257773438 
BRCA1 Lebanon  S955X c.2864C>A p.Ser955Ter rs80357295 4 PC 
BRCA1 Lebanon  604delTG c.485_486del p.Val162Glufs rs80357708 1 257773438 
BRCA1 Macedonia   c.4356del p.Ala1453Glnfs -  29335924 
BRCA1 Macedonia  Q538X c.1612C>T p.Gln538Ter rs80356893 3 29335924 
BRCA1 Macedonia  2792dupA c.2933dup p.Tyr978Ter rs878853292 - 29335924 
BRCA1 Morocco  5061delA c.4945del p.Arg1649Glufs rs80357761 1 23289006 
BRCA1 Morocco  2924delA c.2805del p.Asp936Ilefs rs397509012 1 22425665 
BRCA1 Morocco  3398delC c.3279del p.Tyr1094Ilefs rs397509050 1 22425665 

















BRCA1 Morocco  K1648X c.4942A>T p.Lys1648Ter -  23289006 
BRCA1 Romania  2360delC c.2241del p.Asp749Ilefs rs80357650 2 23958087 
BRCA1 Romania 1 2356insC c.2241dup p.Lys748Glnfs rs397508953 - 20567915 








































































































































































































































































BRCA1 Slovenia 3 C39Y c.116G>A p.Cys39Tyr rs80357498 5 12461697 



















BRCA1 Slovenia  Q1240X c.3718C>T p.Gln1240Ter rs80356903 6 28740454 
BRCA1 Slovenia 1 3137delTTCA c.3018_3021del p.His1006Glnfs rs80357749 2 28740454 
BRCA1 Slovenia 2 K1793X c.5377A>T p.Lys1793Ter rs397509274 - 12461697 
BRCA1 Slovenia 1 576delAG c.457_458del p.Ser153Cysfs rs397509185 - 21232165 
BRCA1 Tunisia 2  c.211dup p.Arg71Lysfs rs397508938 2 23697973 
BRCA1 Tunisia  3461del4 c.3342_3345del p.Glu1115Ter rs397509058 2 23697973 
BRCA1 Tunisia  2789delG c.2551del p.Glu851Asnfs rs397508977 - 23697973 
BRCA1 Tunisia  IVS5+2insG c.212+2T>C  rs80358026 1 23697973 

















BRCA1 Turkey 1 3664delA c.3545del p.Gln1182Argfs - - 24884828 
BRCA1 Turkey  Q957X c.2869C>T p.Gln957Ter rs80356973 3 12655560 

















BRCA1 Turkey  5154delC c.5035del p.Leu1679Ter rs80357896 2 21156238 
BRCA1 Turkey  2990insA c.2871_2872insA p.Phe958Ilefs rs80357693 1 24884828 

















BRCA1 Turkey  2595delA c.2476del p.Thr826Glnfs rs80357631 8 10952777 
BRCA1 Turkey  Y1463X c.4389C>A p.Tyr1463Ter rs80356997 4 10952777 
BRCA1 Turkey  IVS14+1G>A c.4484+1G>A  rs80358063 2 10952777 
BRCA1 Yugoslavia  3447del4 c.3331_3334del  rs80357777 2 10523726 
BRCA2 Algiers  7882insA c.7654dup p.Ile2552Asnfs rs879255463 - 26997744 
BRCA2 Algiers  8560del301 c.8332_8632del p.Ile2778Lysfs -  26997744 
BRCA2 Algiers  6678delA c.6450del p.Val2151Phefs rs886038148 - 26997744 
BRCA2 Bosnia 1 4162_4166delACTTT c.4162_4166del p.Thr1388Phefs rs750704702 - PC 
BRCA2 Bulgaria 1 8760delAA  p.Glu2846Glyfs rs397507990 - 26183948 
BRCA2 Croatia  W2725X c.8175G>A p.Trp2725Ter rs397507965 - 22366370 
BRCA2 Croatia  6869insC c.6641dup p.Tyr2215Leufs rs80359613 1 22366370 
BRCA2 Cyprus 1 9007insA c.8779dup p.Arg2927Lysfs -  27882536 
BRCA2 Cyprus 1 5408delA c.5180dup p.Asn1727Lysfs rs397507769 1 27882536 
BRCA2 Cyprus 5 3758del4 c.3530_3533del p.Asp1177Alafs rs886040481 - 27882536 
BRCA2 Cyprus 4 C1913X c.5739T>A p.Cys1913Ter rs397507801 - 12552570 
 
 
BRCA2 Cyprus 1 6308insA c.6081dup p.Glu2028Argfs rs886040633 - 27882536 
BRCA2 Cyprus 29 8984delG c.8756del p.Gly2919Valfs rs80359728 2 15172753 
BRCA2 Cyprus 1 9005insT c.8777dup p.Leu2926Phefs -  27882536 
BRCA2 Cyprus 3 2232delG c.2004del p.Lys669Asnfs -  27882536 
BRCA2 Cyprus 1 2876delTCTinsG c.2648_2650delinsG p.Phe883Cysfs -  27882536 
BRCA2 Cyprus 1 6319insA c.6091dup p.Thr2031Asnfs rs587782717 - 27882536 
BRCA2 Egypt  S2978X c.8933C>A p.Ser2978Ter rs80359144 1 23877192 
BRCA2 Greece 1 8821delC c.8592del p.Ala2864fs -  PC 
BRCA2 Greece 1 A3205L c.9613_9614delinsCT p.Ala3205Leu rs276174926 6 PC 



















BRCA2 Greece 1 6295del10 c.6067_6076del p.Asp2023Glnfs rs886040632 - PC 
BRCA2 Greece 3 1633delGA c.1405_1406del p.Asp469Ter rs397507586 - PC 
BRCA2 Greece 1 Q1931X c.5791C>T p.Gln1931Ter rs80358807 1 PC 
BRCA2 Greece 1 Q2164X c.6490C>T p.Gln2164Ter rs397507860 - 24010542 
BRCA2 Greece 1 9028delC c.8800del p.Gln2934Lysfs rs886040793 - PC 
BRCA2 Greece 1 Q3126X c.9376C>T p.Gln3126Ter rs80359210 3 24010542 
BRCA2 Greece 1 Q373X c.1117C>T p.Gln373Ter rs397507572 - 27165220 
BRCA2 Greece 1 Q756X c.2266C>T p.Gln756Ter -  PC 
BRCA2 Greece 2 4147delG c.3919del p.Glu1307Lysfs rs80359416 1 11754111 
BRCA2 Greece 2 4883del4 c.4654_4657del p.Gly1552Leufs -  PC 
BRCA2 Greece 1 G4X c.10G>T p.Gly4Ter rs397507571 - 17902052 
BRCA2 Greece 1 7591delC c.7363del p.His2455Ilefs rs886040702 - PC 
BRCA2 Greece 1 4637delTA c.4409_4410del p.Ile1470Lysfs rs80359446 1 17453335 
BRCA2 Greece 2 766insT c.537dup p.Ile180Tyrfs -  PC 
BRCA2 Greece 1 4093del4 c.3865_3868del p.Lys1289Alafs rs80359412 3 PC 
BRCA2 Greece 3 4998delA-ter1600 c.4769del p.Lys1590Serfs rs879255328  24010542 
BRCA2 Greece 1 8774delA c.8546del p.Lys2849Argfs rs397507991 - PC 
BRCA2 Greece 2 4743del11 c.4515_4525del p.Phe1506Thrfs rs863224827 - PC 



















BRCA2 Greece 4 4758delC c.4530del p.Pro1511Asnfs -  PC 
BRCA2 Greece 1 6828delTT c.6600_6601del p.Ser2201Ter rs80359607 2 24010542 
BRCA2 Greece 2 9218del32 c.8993_9024del p.Ser2998Leufs rs886040809 - PC 
BRCA2 Greece 1 9976insT c.9748dup p.Ser3250Phefs rs886040850 - 24010542 
BRCA2 Greece 1 S511X c.1532C>A p.Ser511Ter -  PC 



















BRCA2 Greece 6 7169delC c.6941del p.Thr2314Lysfs rs80359628 1 PC 
BRCA2 Greece 2 W2788X c.8364G>A p.Trp2788Ter rs80359080 1 PC 
BRCA2 Greece 1 9243delAT c.9016_9017del p.Tyr3006Glnfs rs80359739 1 PC 
BRCA2 Greece 2 2718insT c.2490_2491insT p.Val831Cysfs rs886040430 - PC 
 
 
BRCA2 Greece 4 IVS16-2Α>Τ c.7806-2A>T  -  PC 
BRCA2 Greece 1 IVS21+1G>T c.8754+1G>A  -  PC 
BRCA2 Greece 4 IVS25+1G>A c.9501+1G>A  -  PC 
BRCA2 Greece 1 IVS8-1G>C c.682-1G>C  rs81002831 2 PC 
BRCA2 Greece 2 IVS22+1G>T c.8953+1 G>T  rs81002882 2 25382762 
BRCA2 Iran  6216insA c.5984dup p.Asn1995Lysfs rs397507818 - 27165220 
BRCA2 Iran 1 C3097X c.9291T>A p.Cys3097Ter rs397508044 - 27165220 
BRCA2 Iran 1 Q175X c.523C>T p.Gln175Ter rs750385844 - 27165220 



















BRCA2 Iran 1 4446del4 c.4218_4221del p.Lys1406Asnfs rs80359435 1 12100744 
BRCA2 Iran 1 459del22 c.231_252del p.Pro78Glyfs -  PC 
BRCA2 Iran 1 S1341X c.4022C>G p.Ser1341Ter -  PC 
BRCA2 Iran 1 6261insGT c.6033_6034insGT p.Ser2012Valfs rs397507824 - 12100744 
BRCA2 Iran 1 6489insGT c.6261_6262insGT p.Thr2088Valfs -  12100744 
BRCA2 Iran 1 3003delT c.2775del p.Thr926Profs rs1064793063 - PC 
BRCA2 Iran 1 W2830X c.8490G>A p.Trp2830Ter rs587776351 - 27165220 
BRCA2 Iran MBC 1 W3106X c.9317G>A p.Trp3106Ter rs80359205 1 27478808 
BRCA2 Israel  7887delC c.7659del p.Asn2553Lysfs -  PC 
BRCA2 Israel  3185insA c.2957dup p.Asn986Lysfs rs80359365 2 PC 

















BRCA2 Israel  8133insA c.7905dup p.Cys2636Metfs -  PC 
BRCA2 Israel  3339del46 c.3111_3157del p.Gln1037Hisfs -  PC 
BRCA2 Israel  Q1595X c.4783C>T p.Gln1595Ter rs886040549 - PC 
BRCA2 Israel  2082delCinsAA c.1854delinsAA p.Gln619Thrfs rs276174815 1 PC 
BRCA2 Israel  2589delT c.2589del p.Gln864Lysfs rs397507632 - PC 
BRCA2 Israel 1 6854delTA c.6626_6627del p.Ile2209Argfs rs80359610 1 20960228 
BRCA2 Israel  1805insA c.1813dup p.Ile605Asnfs rs1253401667 - PC 
BRCA2 Israel  5219dup c.5219dup p.Leu1740Phefs rs886040583 - PC 
BRCA2 Israel  1155ins c.925dup p.Ser309Phefs rs886038058 - PC 
BRCA2 Israel  3782delCA c.3554_3555del p.Thr1185Serfs rs80359389 2 PC 
BRCA2 Israel  6847insA c.6619dup p.Thr2207Asnfs -  PC 
BRCA2 Israel  2845delT c.2845del p.Tyr949Metfs rs397507644 - PC 
BRCA2 Israel  5057delTG c.4829_4830del p.Val1610Glyfs rs80359468 4 PC 
BRCA2 Israel  IVS15+1G>T c.7618+1G>T  rs397507922 1 PC 
BRCA2 Israel  IVS13-2A>T c.7008-2A>T  rs81002823 5 PC 
BRCA2 Italy 1 3040del4 c.2812_2815del p.Ala938Profs rs80359354 1 PC 
BRCA2 Italy 1  c.842_843del p.Asp281Alafs rs886040773 - PC 
BRCA2 Italy 6  c.6468_6469del p.Gln2157Ilefs rs80359596 1 PC 
BRCA2 Italy 3  c.7681_7682insT p.Gln2561Leufs rs397507933 - PC 
BRCA2 Italy 1 Q2561X c.7681C>T p.Gln2561Ter rs80358994 3 PC 
 
 



















BRCA2 Italy 1 6310del5 c.6082_6086del p.Glu2028Lysfs rs80359558 1 PC 
BRCA2 Italy 1 9683delAG c.9455_9456del p.Glu3152Glyfs rs80359764 3 PC 
BRCA2 Italy 1  c.9498del p.Glu3167Argfs rs397508055 - PC 
BRCA2 Italy 1 1636insG c.1408dup p.Glu470Glyfs rs80359284 1 PC 
BRCA2 Italy 1  c.7251_7252del p.His2417Glnfs rs397507907 - PC 



















BRCA2 Italy 5 1466delT c.1238del p.Leu413Hisfs rs80359271 6 PC 
BRCA2 Italy 4 L557X c.1670T>G p.Leu557Ter rs80358452 2 PC 
BRCA2 Italy 1 9480del4insTT c.9252_9255delinsTT p.Lys3084Asnfs rs276174918 2 PC 
BRCA2 Italy 1 1676dupCAGT c.1448_1451dup p.Lys485Serfs rs886040366 - PC 
BRCA2 Italy 2 K944X c.2830A>T p.Lys944Ter rs80358533 6 PC 
BRCA2 Italy 1  c.3723_3725delinsAT p.Phe1241Leufs rs397507682 - PC 



















BRCA2 Italy 1 928delT c.700del p.Ser234Profs rs80359633 3 PC 
BRCA2 Italy 1 1481C>A c.1253C>A p.Ser418Ter rs397507266 - PC 



















BRCA2 Italy 1 W3127X c.9380G>A p.Trp3127Ter rs80359211 5 PC 
BRCA2 Italy 5 9904delT c.9676del p.Tyr3226Ilefs rs80359774 2 PC 
BRCA2 Italy 1  c.428dup p.Val144Cysfs rs886040519 - PC 



















BRCA2 Italy 2 IVS18+2T>C c.8331+2T>C  - - PC 
BRCA2 Italy 1  c.8488-1G>T  - - PC 
BRCA2 Italy 2 IVS19+1G>A c.8487+1G>A  rs81002798 7 PC 
BRCA2 Italy 5 IVS21-1G>A c.8755-1G>A  rs81002812 6 PC 
BRCA2 Italy 2 IVS5-2A>G c.476-2A>G  rs81002853 7 PC 
BRCA2 Italy 1 IVS26-2A>G c.9649-2A>G  rs81002895 1 PC 
BRCA2 Jordan 1 6862del4 c.6634_6637del p.Cys2212Leufs rs397507871  29335924 
BRCA2 Jordan 2 E2229X c.6685G>T p.Glu2229Ter rs730881548 - 29335924 
BRCA2 Jordan 1 6855del8 c.6627_6634del p.Ile2209Metfs rs397507870 - 29335924 
BRCA2 Jordan 1 L2039X c.6116T>A p.Leu2039Ter - - 29335924 
BRCA2 Jordan 2 1461insA c.1233_1234dup p.Pro412Thrfs rs80359270 1 29335924 
BRCA2 Jordan 1 IVS23-1G>T c.9118-1G>T  - - 29335924 
BRCA2 Kuwait 1 C138X c.414T>A p.Cys138Ter - - PC 



















BRCA2 Lebanon  902delC c.674del p.Thr225Ilefs rs886038054 - 257773438 
BRCA2 Lebanon  IVS24+1G>A c.9256+1G>A  rs81002883 4 257773438 
BRCA2 Macedonia   c.7895del p.Ala2632Glufs - - 29335924 
BRCA2 Macedonia   c.9304del p.Ala3102Glnfs - - 29335924 
BRCA2 Macedonia  D2723G c.8168A>G p.Asp2723Gly rs41293513 6 24052750 
BRCA2 Macedonia   c.7813_7816del p.Cys2605Thrfs - - 29335924 
BRCA2 Macedonia   c.9076C>T p.Gln3026Ter rs80359159 3 29335924 
BRCA2 Macedonia  379G>T c.151G>T p.Glu51Ter - - 29335924 
BRCA2 Macedonia  1827delTG c.1599_1600del p.Glu534Serfs rs80359293 1 29335924 
BRCA2 Macedonia  9580delAT c.9352_9353del p.Met3118Valfs rs786203318 - 29335924 
BRCA2 Macedonia  8545del14 c.8317_8330del p.Ser2773Aspfs rs397507976 - 29335924 
BRCA2 Macedonia   c.4707_4708del p.Tyr1569Ter - - 29335924 
BRCA2 Morocco  7338delA c.7110del p.Lys2370Asnfs rs397507897 - 22425665 
BRCA2 Morocco  3609delT c.3381del p.Phe1127Leufs rs397507666 1 22425665 

















BRCA2 Romania  E2984X c.8680C>T p.Glu2894Ter rs397508002 - 20567915 

































































































































































BRCA2 Serbia 1 1991del4 c.1763_1766del p.Asn588Serfs rs80359303 5 23635950 
BRCA2 Serbia 1 7511delT c.7283del p.Leu2428Trpfs rs483353119 1 23635950 




























BRCA2 Slovenia 1 Q1089X c.3265C>T p.Gln1089Ter rs80358573 1 12461697 
BRCA2 Slovenia  5349C>T c.5101C>T p.Gln1701Ter rs397507758 - 22923021 
BRCA2 Slovenia 1 Q2435X c.7303C>T p.Gln2435Ter rs397507910 - 12461697 
BRCA2 Slovenia 1 1003delAG c.778_779delG p.Glu260Serfs rs80359677 1 21232165 
BRCA2 Slovenia 1 E3096X c.9286G>T p.Glu3096Ter rs80359199 1 21232165 
BRCA2 Slovenia 1 5836delTCinsAG c.5609_5610delinsAG p.Phe1870Ter - 3 12461697 
 
 
BRCA2 Slovenia  3972del4 c.3744_3747del p.Ser1248Argfs rs80359403 8 22923021 
BRCA2 Slovenia 4 5518delTC c.5290_5291del p.Ser1764Lysfs rs80359503 2 21232165 
BRCA2 Slovenia 4 5519C>G c.5291C>G p.Ser1764Ter rs397507778 - 21232165 
BRCA2 Tunisia 1 1537del4 c.1311_1314del p.Lys437Ilefs rs886038065 7 17922257 
BRCA2 Tunisia  5909InsA c.5681dup p.Tyr1894Ter rs80359527 5 23697973 
BRCA2 Turkey 1 6880InsG c.6652dup p.Asp2218Glyfs rs397507874 - 11044644 
BRCA2 Turkey  Q421X c.1261C>T p.Gln421Ter rs80358419 2 24884828 
BRCA2 Turkey  E1250X c.3748G>T p.Glu1250Ter rs80358615 1 10952777 
BRCA2 Turkey  9255delT c.9027del p.His3010Ilefs rs80359742 1 12655560 
BRCA2 Turkey  4693A>T c.4465A>T p.Lys1489Ter  - 21156238 
BRCA2 Turkey  K467X c.1399A>T p.Lys467Ter rs80358427 2 24884828 
BRCA2 Turkey  S2219X c.6656C>G p.Ser2219Ter rs80358893 2 10952777 
BRCA2 Turkey  8643InsA c.8415dup p.Ser2806Ilefs rs397507985 - 10952777 
BRCA2 Turkey  S2835X c.8504C>A p.Ser2835Ter rs80359102 1 21156238 
BRCA2 Turkey  8733delA c.8505del p.Ser2836Leufs rs80359713 1 24884828 
BRCA2 Turkey  5295InsA c.5073dup p.Trp1692Metfs rs80359480 - 10952777 
BRCA2 Turkey  6910InsG c.6682dup p.Val2228Glyfs rs80359621 1 24884828 
BRCA2 Turkey  1620insT c.1392_1393insT p.Val465Cysfs rs397507585 - 21156238 
 
BIC – Breast cancer information core (https://research.nhgri.nih.gov/bic/) 
 
HGVS – Human genome variation society (https://www.hgvs.org/) 
 
dbSNP – database of Single nucleotide polymorphisms  (https://www.ncbi.nlm.nih.gov/snp/) 
